Price T Rowe Associates Inc Terns Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,504,238 shares of TERN stock, worth $6.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,504,238
Previous 1,475,679
1.94%
Holding current value
$6.11 Million
Previous $12.3 Million
32.28%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TERN
# of Institutions
164Shares Held
87.1MCall Options Held
536KPut Options Held
327K-
Soleus Capital Management, L.P. Greenwich, CT8.14MShares$33.1 Million3.16% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$30.7 Million1.14% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$28 Million7.51% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$22.6 Million1.37% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.75MShares$19.3 Million0.17% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $153M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...